Cyberonics panel date finalized
This article was originally published in The Gray Sheet
Executive Summary
VNS vagus nerve stimulation therapy for depression will go before FDA's Neurological Devices Panel June 15, CDRH says, confirming company's announcement (1"The Gray Sheet" April 5, 2004, p. 8). A PMA supplement covers adjunctive treatment of chronic or recurrent depression for patients resistant to antidepressants...
You may also be interested in...
Cyberonics VNS Depression Treatment Panel Review Tentatively Set For June
FDA's Neurological Devices Advisory Panel will review a PMA supplement for Cyberonics' VNS Therapy depression indication June 15, the firm says
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.